Press Release - Laboratory Relocation

Press Release 16 March 2000

Cleansorb Relocates Laboratory To Research Park.

For Immediate Release:

Cleansorb is pleased to announce that it has relocated its laboratory to the Surrey Technology Centre on the Surrey Research Park, University of Surrey, Guildford, Surrey.

Cleansorb will use the Guildford laboratory for both in-house Research and Development and to provide technical support for its commercial oil and gas well stimulation treatments.

The Centre provides serviced space for small technology (research, development and design) companies in one of the most prestigious Science Parks in the UK. The building is at the entrance to the 28.5 Ha (70 acre) Surrey Research Park.

Guildford has excellent road and rail links with London Waterloo 38 minutes away by rail. It is convenient for both London Heathrow and London Gatwick airports.

The address for the laboratory is:
Cleansorb Limited,
The Surrey Technology Centre,
40 Occam Road,
The Surrey Research Park,
Guildford,
Surrey,
GU2 5YG
Tel ++ 44 (0)1483 295090

Notes for editors

1. Cleansorb Limited, with its registered office in Guildford, Surrey, UK, is a privately owned biotechnology company which specialises in developing catalyst-based (especially enzyme-based) processes which assist oil and gas production. Contact: Ian McKay, Tel. ++ 44 (0)1483 295090.

2. Cleansorb's lead product is Arcasolve, a patented and highly effective method of acidising oil and gas wells in which acid is generated in-situ using enzyme catalysts. In-situ generation ensures excellent zonal coverage. The process has particular application in the removal of drilling fluid damage, deep matrix acidising and the stimulation of fracture networks as well as other acidizing applications.

3. Cleansorb is currently developing other enzyme-based processes for the oil industry. It has recently won a SMART award from the UK Department of Trade and Industry (DTI). These awards were introduced in 1988 to encourage innovation and awards are made on a competitive basis to individuals and independent small and medium companies (SMEs). The SMART project is evaluating the feasibility of using enzymes for the controlled deposition of scale inhibitors.